Close

Endocyte (ECYT) Presents Positive Data from TARGET Phase 2b

September 29, 2014 6:14 AM EDT Send to a Friend
Endocyte (Nasdaq: ECYT) announced that the small molecule drug conjugate (SMDC) vintafolide in combination with docetaxel extended overall survival (OS) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login